Skip to main content
. Author manuscript; available in PMC: 2022 Oct 24.
Published in final edited form as: Curr Cardiol Rep. 2022 Oct 24;24(12):2043–2056. doi: 10.1007/s11886-022-01799-x

Table 2.

Comparison of Select Hybrid Closed Loop Systems

Medtronic 670G/770G Medtronic 780G* t:slim X2 Control IQ Omnipod 5
Term for Automated Insulin Delivery “Auto Mode” “Smart Guard” “Control-IQ” “Automated Mode”
Age of Approval (years) 7+ (670G)
2+ (770G)
7+ 6+ 6+
Basal Rate Automation “Auto Basal”
Basal rates based on total daily insulin from previous 2-6 days
“Auto Basal”
Basal rates based on total daily insulin from previous 2-6 days
“Control IQ”
Can increase or decrease the programmed basal rates
“Adaptive Basal”
Basal rates determined from total daily insulin since last pump change
Correction Bolus Dose Automation No Yes, IF:
Glucose >120 mg/dL AND at maximum “auto basal” delivery
Yes, IF:
Glucose predicted to reach >180 mg/dL
Maximum 1 dose per hour
Delivers 60% of calculated dose from programmed settings
No
Algorithm Target Glucose 120 mg/dL Select 100, 110, or 120 mg/dL 112.5-160 mg/dL range Select 110, 120, 130, 140, or 150 mg/dL
Special Features “Temporary Target”: changes target glucose to 150 mg/dL (30 minutes-12 hours) “Temporary Target”: changes target glucose to 150 mg/dL (30 minutes-24 hours)
Extended wear (7 day) insulin infusion set
“Exercise Activity”: changes target glucose range to 140-160 mg/dL
“Sleep Activity”: changes target range to 112.5-120 mg/dL and prevents automated correction bolus
“Activity Feature”: changes target glucose to 150 mg/dL and reduces insulin delivery (1-24 hours)
User can control basal or bolus dosing remotely from cell phone

References for Table 2 information: (138, 139)

*

At the time of writing, system CE marked in Europe but under review for United States FDA approval.